Hjem
Lars A. Akslens bilde

Lars A. Akslen

Professor, Leder for CCBIO
  • E-postLars.Akslen@uib.no
  • Telefon+47 55 97 31 82
  • Besøksadresse
    Patologisk avdeling, Sentralblokka 2 etg., Haukeland Universitetssjukehus (HUS)
    evt. CCBIO, Sentralblokka 2 etg., HUS
  • Postadresse
    Postboks 7804
    5020 Bergen

Akslen er en sertifisert spesialist i kirurgisk patologi og leder forskningsgruppen Tumor Biology Research Group (etablert i 1995) ved Klinisk Institutt 1, Universitetet i Bergen. Siden 2013 har Akslen vært senterleder for Centre for Cancer Biomarkers CCBIO. Akslens gruppe og CCBIO arbeider med translasjonell kreftforskning med fokus på nye kreftmarkører og målrettet behandling og særlig mekanismer knyttet til hvordan kreftceller påvirkes av mikromiljøet i svulstene, og den betydning dette har for kreftspredning og dårlig prognose. Gruppen har prosjekter på ulike kreftformer, som brystkreft, ondartet melanom, prostatakreft og gynekologisk kreft. Gruppen kombinerer studier av humane tumorprøver med eksperimentelle celle- og dyremodeller. Det overordnede målet er å finne nye biomarkører som kan hjelpe oss til å forutse hvordan aggressive svulster vil utvikle seg og dermed bedre kunne skreddersy behandling.

Vitenskapelig artikkel
  • 2010. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Medicine. 12 sider.
  • 2010. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer. 15 sider.
  • 2010. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America. 1124-1129.
  • 2009. Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes. Clinical Cancer Research. 2302-2310.
  • 2009. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 575-582.
  • 2009. Secondary breast cancer: a 5-year population-based study with review of the literature. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 762-767.
  • 2009. Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proceedings of the National Academy of Sciences of the United States of America. 12115-12120.
  • 2009. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Research. 4708-4715.
  • 2009. Plasma calprotectin concentrations in women with endometrial carcinoma. Gynecologic Oncology. 491-495.
  • 2009. Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas. BMC Cancer. 425.
  • 2009. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America. 4834-4839.
  • 2009. Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas. Clinical Cancer Research. 1417-1427.
  • 2009. Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma. Histopathology. 174-183.
  • 2009. Identification of a CDK4 R24H mutation-positive melanoma family by analysis of early-onset melanoma patients in Latvia. Melanoma research. 119-122.
  • 2009. Hyperoxic treatment induces mesenchymal to epithelial transition in a rat adenocarcinoma model. PLOS ONE.
  • 2009. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. Journal of Clinical Pathology. 139-146.
  • 2009. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. British Journal of Cancer. 1282-1289.
  • 2009. Estrogen receptor β– an independent prognostic marker in estrogen receptor α and progesterone receptor-positive breast cancer? Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 644-650.
  • 2009. Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. American Journal of Obstetrics and Gynecology. 603-607.
  • 2009. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clinical Cancer Research. 3484-3494.
  • 2008. WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clinical Cancer Research. 1397-1406.
  • 2008. Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer. 362-372.
  • 2008. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes, Chromosomes and Cancer. 175-184.
  • 2008. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma research. 29-35.
  • 2008. Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. British Journal of Cancer. 1662-1669.
  • 2008. Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Modern Pathology. 583-590.
  • 2008. Lesson of the Month - Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. Histopathology. 370-380.
  • 2008. Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. Radiotherapy and Oncology. 435-442.
  • 2008. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. International Journal of Oncology. 307-316.
  • 2008. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. American Journal of Obstetrics and Gynecology. e 1-7.
  • 2008. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 8713-8717.
  • 2007. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 11 sider.
  • 2007. ERG upregulation and related ETS transcription factors in prostate cancer. International Journal of Oncology. 19-32.
  • 2007. Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry. 46-58.
  • 2007. A Switch from E-Cadherin to N-Cadherin Expression Indicates Epithelial to Mesenchymal Transition and Is of Strong and Independent Importance for the Progress of Prostate Cancer. Clinical Cancer Research. 7003-7011.
  • 2006. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Research. 3303-3309.
  • 2006. Role of angiogenesis in human tumor dormancy - Animal models of the angiogenic switch. Cell Cycle. 1779-1787.
  • 2006. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. American Journal of Obstetrics and Gynecology. 979-986.
  • 2006. Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients. International Journal of Cancer. 1227-1233.
  • 2006. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical 14 retropubic prostatectomy for localized prostate cancer? BJU International. 51-55.
  • 2006. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Molecular Cancer Therapeutics. 2914-2918.
  • 2006. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid. 161-175.
  • 2006. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clinical Cancer Research. 1168-1174.
  • 2006. Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Archiv. 68-74.
  • 2006. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Journal of Clinical Oncology. 268-273.
  • 2006. Body size and thyroid cancer in two million Norwegian men and women. British Journal of Cancer. 366-370.
  • 2005. Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. British Journal of Cancer. 933-938.
  • 2005. Low frequency of BRAF and CDKN2A mutations in endometrial cancer. International Journal of Cancer. 930-934.
  • 2005. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clinical Cancer Research. 8606-8614.
  • 2005. Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Research. 634-644.
  • 2005. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiology, Biomarkers and Prevention. 1108-1112.
  • 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clinical Cancer Research. 5582-5588.
  • 2003. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 1011-1018.
  • 2003. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer. 438-446.
  • 2003. Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis. Gynecologic Oncology. 218-25.
  • 2003. MSI-low, a real phenomenon which varies in frequency among cancer types. Journal of Pathology. 389-94.
  • 2003. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Journal of the National Cancer Institute. 1482-85.
  • 2003. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clinical Cancer Research. 1474-1479.
  • 2003. Benign growth of different prostate zones in aging men with slightly elevated PSA in whom prostate cancer has been excluded: a prospective study of 510 patients. Urology. 447-450.
  • 2002. Molecular pathogenesis and prognostic factors in endometrial carcinoma. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 673-689.
  • 2002. Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clinical Cancer Research. 138-43.
  • 2002. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer. 2185-91.
  • 2002. Can we rely on pathologic parameters to define conservative treatment of papillary thyroid carcinoma? International Journal of Surgical Pathology. 267-272.
  • 2001. Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Research. 7 sider.
  • 2001. Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway. Cancer Epidemiology, Biomarkers and Prevention. 113-117.
  • 2001. Expression of oestrogen and progesterone receptorss, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African poplation. East African Medical Journal. 360-5.
  • 2001. Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas. Oncogene. 885-892.
  • 2000. Molecular portraits of human breast tumours. Nature. 747-52.
  • 2000. Frequent loss of p16 protein expression and high proliferative activity (Ki-67) in malignant melanoma from black Africans. Anticancer Research. 4857-62.
  • 1999. The PTEN gene is methylated in endometrial carcinoma and associated with advanced disease and microsattelite instability. (Abs. no. 207). American Journal of Human Genetics. S. 209.
  • 1999. TP53 as a predictor of response to chemotherpy in breast cancer. RSO Scientific Updates. 73-88.
  • 1999. TP53 as a predictor of response to chemotherapy in breast cancer. European School of Oncology Scientific Updates. 73-88.
  • 1999. Significance of tumor associated macrophages. VEGF and TSP-1 expression for tumor angiogenesis and prognosis in endometrial carcinomas. International Journal of Cancer. 539-543.
  • 1999. Significance of tumor associated macrophages, VEGF and TSP-1 for angiogenesis and prognosis of endometrial carcinoma. International Journal of Cancer. 538-43.
  • 1999. Prognostic significance of tumor angiogenesis, Ki-67, p53 and p21 expression - a population-based endometrial carcinoma study. Journal of Clinical Oncology. 1382-1390.
  • 1999. Prognostic significance of angiogenesis, Ki-67, p53 and p21 expression - a population-based endometrial carcinoma study. International Journal of Oncology. 395-399.
  • 1999. Loss of nuclear expression of p16 protein correlates with increased tumor cell proliferation and poor patient outcome in patients with vertical growth phase melanoma. (Abstract no. P-487). Virchows Archiv. 314.
  • 1999. Influence of TP53 gene alterations and Her-2 expression on the respons to treatment with doxorubicin in locally advanced breast cancer. (Abs. no. 227). Breast Cancer Research and Treatment.
  • 1999. Enhanced expression of EGF-receptor and low frequency of ras mutations in X-ray-induced rat thyroid tumours. Virchows Archiv. 434-441.
  • 1999. Clinicopathological characteristics of melanomas of the hand. Journal of Hand Surgery - British and European Volume. 460-64.
  • 1999. Clinicopathological characteristics of melanomas of the hand. Journal of Hand Surgery - British and European Volume. 460-64.
  • 1998. Økt forekomst av kreft i skjoldkjertelen blant norske kvinner gift med fiskere. Tidsskrift for Den norske legeforening. 4202-4205.
  • 1998. Seasonal variations in the presentation and growth of thyroid cancer. British Journal of Cancer. 1174-1179.
  • 1998. Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
  • 1998. Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
  • 1998. Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
  • 1998. Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
  • 1998. Prognostic impact of morphometric nuclear grade of endometrial carcinoma. Cancer. 956-964.
  • 1998. Prognostic impact of morphometric nuclear grade in endometrial carcinoma. Cancer. 956-964.
  • 1998. Poorer survival of nulliparous women with endometrial carcinoma. Cancer. 1328-1333.
  • 1998. Independent prognostic importance of microvessel density in endometrial carcinoma. British Journal of Cancer. 1140-1144.
  • 1998. Independent prognostic importance of microvessel density in endometrial carcinoma. British Journal of Cancer. 1140-1144.
  • 1998. Identification of high-risk patients by assessment of nuclear Ki67 expression in a prosepective study of endometrial carcinoma patients. Clinical Cancer Research. 2779-2785.
  • 1998. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clinical Cancer Research. 2779-2785.
  • 1998. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. International Journal of Cancer. 91-95.
  • 1998. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. International Journal of Cancer. 91-95.
  • 1998. Diagnostisk molekylærbiologi ved solide svulster: Thyreoideacancer. Tidsskrift for Den norske legeforening. 2199-2203.
  • 1998. Diagnostisk molekylærbiologi ved solide svulster - thyreoidea. Tidsskrift for Den norske legeforening. 2199-2203.
  • 1998. Decreased survival for nulliparous women with endometrial carcinoma. Is the relationship due to biology or behaviour? Cancer. 1328-1333.
  • 1997. Recurrence of endometrial carcinoma and the value of routine follow up. British Journal of Obstetrics and Gynaecology. 1302-1307.
  • 1997. Recurrence of endometrial carcinoma and the value of routine follow up. British Journal of Obstetrics and Gynaecology. 1302-1307.
  • 1997. Prognostisk betydning av tumorbiologiske markører ved kreft i livmorslimhinnen. Kreftnytt. 4-7.
  • 1997. Increased risk of thyroid cancer among Norwegian females married to fishery workers. British Journal of Cancer. 385-389.
  • 1997. Expression of p16 protein in prostatic adenocarcinomas, intraepithelial neoplasia and benign/hyperplastic glands. Urologic Oncology. 59-66.
  • 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • 1997. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. International Journal of Cancer. 535-540.
  • 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • 1997. Absence of p21 Expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • 1996. Thyroid carcinomas with tall-cell and columnar-cell features (letter). Current Diagnostic Pathology. 67.
  • 1996. Spesific TP53 gene mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • 1996. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • 1996. Relationship between mutations in the TP53 gene and De Novo resistance and early relapse following treatment with doxorubicin in patients with breast cancer. Nature Medicine. 811-814.
  • 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • 1996. Primary organ-culture of non neoplastic and neoplastic thyroid tissue as multicellular spheroids. International Journal of Oncology. 1071-1078.
  • 1996. Independent prognostic importance of vascular invasion in nodular melanomas. Cancer. 1211-1219.
  • 1996. Incidence of thyroid cancer in New Caledonia, South Pacific, during 1985-1992 (letter). American Journal of Epidemiology. 1174.
  • 1996. Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Research. 1184-1188.
  • 1996. Cytoplasmatic localization of EGF receptor in papillary thyroid carcinomas: Association with the 150-kDa receptor forms. International Journal of Cancer. 161-167.
  • 1996. Aggressive thyroid carcinoma with predominant cribriform growth pattern. Pathology, Research and Practice.
  • 1995. Primary organ culture of non-neoplastic and neoplastic thyroid tissue multicellular spheroids. International Journal of Oncology. 1071-1078.
  • 1995. Primary organ culture of non-neoplastic and neoplastic thyroid tissue as multicellular spheroids. International Journal of Oncology. 1071-1078.
  • 1995. Primary organ culture of non-neoplastic and neoplastic thyroid tissue as multicellular spheroids. International Journal of Oncology. 1071-1078.
  • 1995. Oncoproteins and tumor progression in papillary thyroid carcinoma. Presence of epidermal growth factor receptor (EGF-R), c-erbB-2 protein, estrogen receptor related protein (p29), p21-ras protein and proliferation indicators in relation to tumor recurrences and patients survival. Cancer. 1643-1654.
  • 1995. Oncoproteins and tumor progression in papillary thyroid carcinoma. Presence of epidermal growth factor receptor (EGF-R), c-erbB-2 protein, estrogen receptor related protein (29), p21-ras protein and proliferation indicators in relation to tumor recurrences and patient survival. Cancer. 1643-1654.
  • 1995. Lack of diagnostic value of DNA content and p53 immunostaining in normal, hyperplastic and neoplastic parathyroid tissue. Oncology Reports. 69-72.
  • 1995. Histopatologiens betydning for vurdering av kreftforekomst og kreftårsaker. Tidsskrift for Den norske legeforening. 943-946.
  • 1993. Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. European Journal of Cancer. 44-51.
  • 1993. Prognostic impact of EGF-receptor in papillary thyroid carcinoma. British Journal of Cancer. 808-812.
  • 1992. Reproductive factors and risk of thyroid cancer. A prospective study of 63090 women from Norway. British Journal of Cancer. 772-774.
  • 1992. Differentiated thyroid carcinomas: the relevance of various pathological features for tumour classification and prediction of tumour progress. Virchows Archiv. A, Pathological anatomy and histopathology. 17-23.
Vitenskapelig foredrag
  • 2016. Molecular subtypes of breast cancer: long-term incidence trends and prognostic differences.
  • 2016. FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis.
  • 2013. Molekylære subtyper og overlevelse ved brystkreft.
  • 2013. Molekylære subtyper og overlevelse ved brystkreft.
  • 2012. Multimodal imaging for suspected recurrent differentiated thyroid cancer (DTC): FDG-PET-CT, I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB).
  • 2011. Multimodal imaging for diagnosis and treatment of recurrent differentiated thyroid cancer (DTC)FDG-PET-CT, contrast-enhanced CT (CE-CT), I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB).
  • 2011. In vivo Dynamic Contrast Enhanced MRI & Histopathological Assessment of Tumor Angiogenesis in Luminal-like and Basal-like Breast Cancer Xenografts.
  • 2011. FDG-PET-CT, I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB) for recurrent differentiated thyroid cancer (DTC).
  • 2011. Early vascular response to bevacizumab treatment measured by DCE-MRI in breast cancer xenografts.
  • 2011. DCE-MRI for early therapy monitoring of anti-angiogenic therapy.
  • 2010. Real time elastografi ved cancer prostatae.
  • 2010. Preliminære resultater av PCA3 måling i urin hos pasienter med cancer prostatae.
  • 2010. Multimodal imaging of differentiated thyroid cancer: FDG-PET-CT, I-131-SPECT-CT and ultrasound.
  • 2010. In vivo magnetic resonance imaging and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts.
  • 2010. Er preoperativ MR-prostata nyttig for å avklare korrekt T-stadium forut for kirurgi?
  • 2010. Er MR-prostata nyttig for å avklare videre oppfølgningsbehov hos pasienter med 2 eller flere negative biopsiserier?
  • 2009. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
  • 2009. EMT Promotes Malignant Transformation of Prostate Epithelial Cells in Culture.
  • 2008. Polycomb group target genes and bivalent H3K4 & K27me3 modifications in human embryonic cells were enriched among dysregulated genes in prostate cancer.
  • 2008. Epithelial to mesenchymal transition of a primary, immortalized prostate cell line is associated with gene expression switches of entire cell attachment modules.
  • 2007. Functional oncogenomics and epigenomics analysis of prostate cancer.
  • 2007. Detection of TMPRSS2:ERG translocations in the urine of prostate cancer patients and identification of ERG target genes.
  • 2006. Global gene expression analysis of transcription factors in prostate cancer and cell lines.
  • 2006. ERG upregulation and related transcription factors in prostate cancer.
  • 2004. Gene expression profiling in prostate cancer refined by pairwise comparisons of cDNA microarrays from benign and malignant tissue.
  • 2004. Gene expression profiles in prostate cancer: identification of upregulated SIM2 gene validated in archival tissue, relation to histological grading and prognosis.
  • 2003. Mutation analysis of the RAS-RAF pathway in pancreatic adenocarcinomas and malignant melanomas.
  • 2003. Global analysis of gene expression and regulatory patterns in urogenital tumours using DNA microarrays.
  • 2003. Global analysis of gene expression and regulatory patterns in cancer.
  • 2003. Gene expression profiling in prostate cancer: cluster analysis and association with tumor differentation.
  • 2003. Gene expression profiling in prostate cancer: Cluster analysis and association with tumor differentiation.
  • 2003. Gene expression profiling in prostate cancer.
  • 2003. DNA microarray studies of human cancer - pitfalls and outlook.
  • 2003. Comparison of DNA microarray and real time quantitative PCR for quantitation of gene expression of selected genes in prostate cancer.
  • 2002. Cancer mammae behandlet med brystbevarende kirurgi ved Haukeland sykehus 1984-1995.
  • 2001. Prognostisk betydning av angiogenese (microvessel density - MVD) og proliferasjonsmarkøren Ki-67 ved lokalisert prostatacencer.
  • 1999. Prognostic importance of microvessel density (MVD) in clinically localized prostate cancer.
  • 1998. Prognostic importance of microvessel density (MVD) in clinically localized prostate cancer.
  • 1998. Profylaktisk thyroidectomi hos barn - initial erfaring.
  • 1998. Malignt melanom på hender.
  • 1998. Malignant melanoma of the hand. A 25-year clinico-pathological study.
  • 1997. Independent prognostic importance of microvessel density in endometrial carcinoma. [poster].
  • 1989. Mortality form ischemic heart disease related to life-style differences among Norwegian men (Abstract).
Vitenskapelig antologi/Konferanseserie
  • 2017. Biomarkers of the Tumor Microenvironment: Basic Studies and Practical Applications. Springer.
Sammendrag/abstract
  • 2013. Proliferation markers PHH3, Ki67 and mitotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. Modern Pathology. 50A-50A.
  • 2013. Proliferation markers PHH3, Ki67 and Mimtotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. Laboratory Investigation. 50A-50A.
  • 2013. FOXA1 LOSS IN ENDOMETRIAL CANCER IS ASSOCIATED WITH POOR PROGNOSIS AND ER ALPHA LOSS. International Journal of Gynecological Cancer. 1 sider.
  • 2012. Prognostic impact of proliferation markers Ki-67, PHH3 and mitotic count in breast carcinomas. Virchows Archiv. S5-S5.
  • 2012. Metabolic Responses to VEGF Inhibition in Patient-derived Breast Cancer Xenografts. European Journal of Cancer. S32-S32.
  • 2012. Expression of hypoxia-inducible factor-1a and associations with vascular endothelial growth factor expression, high microvessel density and features of aggressive tumors in African breast cancer. Virchows Archiv. S249-S249.
  • 2012. Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. S18-S18.
  • 2011. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Clinical and Experimental Metastasis. 234-235.
  • 2010. Prognostic importance of vascular proliferation and tumor cell invasion in blood and lymphatic vessels in endometrial carcinoma. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 248-248.
  • 2010. Multimodal imaging of differentiated thyroid cancer: FDG-PET-CT, I-131-SPECT-CT and ultrasound [Abstract]. European Journal of Nuclear Medicine and Molecular Imaging. S291-S291.
  • 2009. Proliferation of immature tumor vessels is a novel marker of clinical progress in prostate cancer. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 233-233.
  • 2008. Vascular proliferation by Nestin/Ki-67 is a novel predictor of the clinical progress of prostate cancer. Histopathology. 276-277.
  • 2008. Candidate stem cell marker ALDH1 expression and relationship with BRCA-mutations and basal-like differentiation in breast carcinoma. Histopathology. 25-25.
  • 2007. Loss of BMI-1 expression is associated with the clinical progress of malignant melanoma. Virchows Archiv. 452-452.
  • 2007. Epithelial to mesenchymal transition is of strong prognostic importance in prostate cancer. Virchows Archiv. 344-344.
  • 2007. Basal-like phenotype is frequent in invasive breast carcinoma from Ugandan Africans and is strongly associated with a high expression of EGFR/c-Kit and features of aggressive tumors. Virchows Archiv. 137-137.
  • 2006. Global gene expression analysis of transcription factors in prostate cancer and cell lines. International Journal of Molecular Medicine. S27.
  • 2006. ERG upregulation in relation to other transcription factors in prostate cancer. NBS-nytt. 72.
  • 2005. Single-minded 2 homolog gene is overexpressed in prostate cancer. Virchows Archiv. 432-432.
  • 2005. Overexpression of ERG and SIM2 transcription factors in prostate cancer. International Journal of Molecular Medicine. S76-S76.
Vitenskapelig oversiktsartikkel/review
  • 2013. Malignt melanom – diagnostikk, behandling og oppfølging i Norge. 2154-2159.
  • 2009. Biologic markers in endometrial cancer treatment. 693-707.
  • 2008. Tumor-vascular interactions and tumor dormancy. 569-585.

Se fullstendig oversikt over publikasjoner i CRIStin.